Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.55 |
| ▸ | PLK1 | P53350 | 15/20 | 0.46 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.46 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.46 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.40 |
| ▸ | TAF1 | P21675 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524048 | 1.00 | BRD4 (0.55) | BRD4PLK1PLK3PLK2RPS6KA6 | |
| SCHEMBL524047 | 1.00 | BRD4 (0.55) | BRD4PLK1PLK3PLK2RPS6KA6 | |
| SCHEMBL20815288 | 1.00 | BRD4 (0.55) | BRD4PLK1PLK3PLK2RPS6KA6 | |
| SCHEMBL523785 | 0.92 | BRD4 (0.54) | BRD4PLK1PLK3PLK2RPS6KA6 | |
| SCHEMBL523786 | 0.92 | BRD4 (0.54) | BRD4PLK1PLK3PLK2RPS6KA6 | |
| SCHEMBL523440 | 0.92 | BRD4 (0.54) | BRD4PLK1PLK3PLK2RPS6KA6 | |
| SCHEMBL20815329 | 0.92 | BRD4 (0.54) | BRD4PLK1PLK3PLK2RPS6KA6 | |
| SCHEMBL10313790 | 0.89 | BRD4 (0.42) | BRD4PLK1PLK3PLK2RPS6KA6 | |
| SCHEMBL12837784 | 0.88 | BRD4 (0.60) | BRD4PLK1PLK3PLK2TAF1 | |
| SCHEMBL384232 | 0.87 | BRD4 (0.62) | BRD4PLK1PLK3PLK2RPS6KA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356122-B1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2019-03-20 | — | — | EP | claimed |
| US-20120322793-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-20 | — | — | US | claimed |
| US-20120028966-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | claimed |
| EP-2356122-A1 | PROTEIN KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2011-08-17 | — | — | EP | claimed |
| WO-2010008454-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-21 | — | — | WO | claimed |
| EP-2356122-B1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20140187774-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-03 | — | — | US | disclosed |
| US-20140187774-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-07-03 | — | — | US | disclosed |
| US-8637666-B2 | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637666-B2 | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-28 | — | — | US | disclosed |
| US-8618106-B2 | Protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120322793-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278297-B2 | Protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120178926-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178926-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120028966-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2356122-A1 | PROTEIN KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010008454-A1 | PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187774-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | CDK20, CDK10, MAPK1 | BRD4 2844/4885PLK1 92/4885PLK3 327/4885 |
| US-20120178926-A1 | METHODS FOR PREPARING PYRIMIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | CDK20, CDK10, MAPK1 | BRD4 2844/4885PLK1 92/4885PLK3 327/4885 |
| US-20120322793-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | BRD4 1038/4885PLK1 86/4885PLK3 479/4885 |
| US-20120028966-A1 | PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | BRD4 1038/4885PLK1 86/4885PLK3 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.